Literature DB >> 32084424

Prostaglandin E2, Produced by Mast Cells in Colon Tissues From Patients With Irritable Bowel Syndrome, Contributes to Visceral Hypersensitivity in Mice.

Gintautas Grabauskas1, Xiaoyin Wu1, Jun Gao1, Ji-Yao Li1, Danielle Kim Turgeon1, Chung Owyang2.   

Abstract

BACKGROUND AND AIMS: Visceral hypersensitivity is common in patients with irritable bowel syndrome (IBS). We investigated whether inflammatory molecules, such as histamine and proteases, activate prostaglandin-endoperoxide synthase 2 (also called COX2) to increase the synthesis of prostaglandin E2 (PGE2) by mast cells, which activates the receptor PTGER2 (also called EP2) in the dorsal root ganglia to promote visceral hypersensitivity.
METHODS: We used an enzyme-linked immunosorbent assay to measure levels of spontaneous release of molecules from mast cells in colonic mucosa from patients with IBS with diarrhea (IBS-D; 18 women and 5 men; aged 28-60 years), healthy individuals (controls, n = 24), mice, and rats. We measured visceromotor responses to colorectal distension in rodents after intracolonic administration of colon biopsy supernatants, histamine, PGE2, a small interfering RNA against EP2, or an agonist of F2R like trypsin receptor 1 (F2RL1, also called protease-activated receptor 2 [PAR2]). We investigated the role of COX2, produced by mast cells, in mediation of visceral hypersensitivity using mice with the Y385F substitution in Ptgs2 (Ptgs2Y385F mice), mast cell-deficient (W/WV) mice, and W/WV mice given injections of mast cells derived from wild-type or Ptgs2Y385F mice.
RESULTS: Colon biopsies from patients with IBS-D had increased levels of PGE2, based on enzyme-linked immunosorbent assay, and COX2 messenger RNA and protein, compared with control biopsies. Immunohistochemistry showed that most of the COX2 was in mast cells. Intracolonic infusions of rats with IBS-D biopsy supernatants generated a 3- to 4-fold increase in visceromotor responses to colorectal distension; this was associated with significant increases in PGE2, histamine, and tryptase in the colonic mucosa. These increases were prevented by a mast cell stabilizer, COX2 inhibitor, or knockdown of EP2. Intracolonic administration of supernatants from biopsies of patients with IBS-D failed to induce visceral hypersensitivity or increase the level of PGE2 in W/WV and Ptgs2Y385Fmice. Reconstitution of mast cells in W/WV mice restored the visceral hypersensitivity response.
CONCLUSIONS: Abnormal synthesis of PGE2 by colonic mast cells appears to induce visceral hypersensitivity in patients with IBS-D.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Keywords:  Abdominal Pain; Dorsal Root Ganglia; Inflammation; Tryptase

Mesh:

Substances:

Year:  2020        PMID: 32084424      PMCID: PMC7282934          DOI: 10.1053/j.gastro.2020.02.022

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  31 in total

Review 1.  Visceral perception: inflammatory and non-inflammatory mediators.

Authors:  L Bueno; J Fioramonti
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

Review 2.  Recent advances in the cellular and molecular biology of mast cells.

Authors:  R L Stevens; K F Austen
Journal:  Immunol Today       Date:  1989-11

3.  Proteinases and proteinase-activated receptor 2: a possible role to promote visceral hyperalgesia in rats.

Authors:  Anne-Marie Coelho; Nathalie Vergnolle; Bruno Guiard; Jean Fioramonti; Lionel Bueno
Journal:  Gastroenterology       Date:  2002-04       Impact factor: 22.682

4.  Prostaglandin E(2) modulates TTX-R I(Na) in rat colonic sensory neurons.

Authors:  Michael S Gold; Lei Zhang; Dena L Wrigley; Richard J Traub
Journal:  J Neurophysiol       Date:  2002-09       Impact factor: 2.714

5.  Terminal ileal mucosal mast cells in irritable bowel syndrome.

Authors:  A P Weston; W L Biddle; P S Bhatia; P B Miner
Journal:  Dig Dis Sci       Date:  1993-09       Impact factor: 3.199

6.  Critical role for mast cells in the pathogenesis of 2,4-dinitrobenzene-induced murine colonic hypersensitivity reaction.

Authors:  Anneke Rijnierse; Andries S Koster; Frans P Nijkamp; Aletta D Kraneveld
Journal:  J Immunol       Date:  2006-04-01       Impact factor: 5.422

7.  Tolerance for rectosigmoid distention in irritable bowel syndrome.

Authors:  W E Whitehead; B Holtkotter; P Enck; R Hoelzl; K D Holmes; J Anthony; H S Shabsin; M M Schuster
Journal:  Gastroenterology       Date:  1990-05       Impact factor: 22.682

8.  Inflammatory cell distribution in colon mucosa as a new tool for diagnosis of irritable bowel syndrome: A promising pilot study.

Authors:  J Boyer; M-C Saint-Paul; B Dadone; S Patouraux; M-H Vivinus; D Ouvrier; J-F Michiels; T Piche; M K Tulic
Journal:  Neurogastroenterol Motil       Date:  2017-10-04       Impact factor: 3.598

9.  Altered rectal perception is a biological marker of patients with irritable bowel syndrome.

Authors:  H Mertz; B Naliboff; J Munakata; N Niazi; E A Mayer
Journal:  Gastroenterology       Date:  1995-07       Impact factor: 22.682

Review 10.  Mast Cells and Irritable Bowel Syndrome: From the Bench to the Bedside.

Authors:  Lei Zhang; Jun Song; Xiaohua Hou
Journal:  J Neurogastroenterol Motil       Date:  2016-04-30       Impact factor: 4.924

View more
  20 in total

1.  Extracorporeal shock wave therapy decreases the number of total and degranulated mast cells and alleviates pelvic pain in a rat model of prostatitis.

Authors:  Zhengyao Song; Chen Jin; Zichen Bian; Chaozhao Liang
Journal:  Mol Cell Biochem       Date:  2021-01-25       Impact factor: 3.396

2.  Mucosal Serotonin Reuptake Transporter Expression in Irritable Bowel Syndrome Is Modulated by Gut Microbiota Via Mast Cell-Prostaglandin E2.

Authors:  Jun Gao; Tingting Xiong; Gintautas Grabauskas; Chung Owyang
Journal:  Gastroenterology       Date:  2022-02-12       Impact factor: 33.883

3.  Significance of hub genes and immune cell infiltration identified by bioinformatics analysis in pelvic organ prolapse.

Authors:  Ying Zhao; Zhijun Xia; Te Lin; Yitong Yin
Journal:  PeerJ       Date:  2020-08-18       Impact factor: 2.984

4.  Research on Correlation Between Psychological Factors, Mast Cells, and PAR-2 Signal Pathway in Irritable Bowel syndrome.

Authors:  Guanqun Chao; Zhaojun Wang; Shuo Zhang
Journal:  J Inflamm Res       Date:  2021-04-14

Review 5.  Mast cell mediation of visceral sensation and permeability in irritable bowel syndrome.

Authors:  William L Hasler; Gintautas Grabauskas; Prashant Singh; Chung Owyang
Journal:  Neurogastroenterol Motil       Date:  2022-03-21       Impact factor: 3.960

6.  Bioinformatics Analysis of Differentially Expressed Genes and Protein-Protein Interaction Networks Associated with Functional Pathways in Ulcerative Colitis.

Authors:  Feng Cao; Yun-Sheng Cheng; Liang Yu; Yan-Yan Xu; Yong Wang
Journal:  Med Sci Monit       Date:  2021-01-19

7.  Mast Cells Induce Ductular Reaction Mimicking Liver Injury in Mice Through Mast Cell-Derived Transforming Growth Factor Beta 1 Signaling.

Authors:  Konstantina Kyritsi; Lindsey Kennedy; Vik Meadows; Laura Hargrove; Jennifer Demieville; Linh Pham; Amelia Sybenga; Debjyoti Kundu; Karla Cerritos; Fanyin Meng; Gianfranco Alpini; Heather Francis
Journal:  Hepatology       Date:  2021-04-19       Impact factor: 17.298

8.  Ginger relieves intestinal hypersensitivity of diarrhea predominant irritable bowel syndrome by inhibiting proinflammatory reaction.

Authors:  Changrong Zhang; Yongquan Huang; Peiwu Li; Xinlin Chen; Fengbin Liu; Qiuke Hou
Journal:  BMC Complement Med Ther       Date:  2020-09-14

Review 9.  The trace aminergic system: a gender-sensitive therapeutic target for IBS?

Authors:  Lesha Pretorius; Carine Smith
Journal:  J Biomed Sci       Date:  2020-09-28       Impact factor: 8.410

10.  Abdominal pain in quiescent inflammatory bowel disease.

Authors:  Matthew D Coates; Ansh Johri; Venkata Subhash Gorrepati; Parth Maheshwari; Shannon Dalessio; Vonn Walter; August Stuart; Walter Koltun; Nana Bernasko; Andrew Tinsley; Emmanuelle D Williams; Kofi Clarke
Journal:  Int J Colorectal Dis       Date:  2020-09-03       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.